Detalhe da pesquisa
1.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Blood
; 139(19): 2931-2941, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007321
2.
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
Haematologica
; 107(11): 2641-2649, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511672
3.
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Blood
; 134(18): 1498-1509, 2019 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31515250
4.
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Am J Hematol
; 95(6): 594-603, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32129512
5.
Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values.
Haematologica
; 104(11): 2200-2205, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30948488
6.
Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.
Blood
; 127(11): 1398-402, 2016 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26817958
7.
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
BMC Cancer
; 18(1): 359, 2018 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29609532
8.
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.
Cancer
; 123(14): 2680-2687, 2017 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28518222
9.
Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3.
Blood
; 135(13): 1062-1066, 2020 03 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32047890
10.
Life, genes, and death in Ph- MPNs.
Blood
; 124(16): 2471-2, 2014 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25323682
11.
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
N Engl J Med
; 366(9): 799-807, 2012 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22375971
12.
Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.
Mod Pathol
; 28(10): 1315-23, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26271725
13.
Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis.
Blood
; 122(11): 1881-6, 2013 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23900239
14.
Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?
Haematologica
; 105(9): 2190-2191, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054041
15.
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Haematologica
; 100(4): 479-88, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25616577
16.
Management of chronic myeloid leukemia in blast crisis.
Ann Hematol
; 94 Suppl 2: S159-65, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25814082
17.
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.
Am J Hematol
; 95(1): E1-E3, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31588594
18.
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
Haematologica
; 99(2): 292-8, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23911705
19.
Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes.
Blood Adv
; 8(10): 2520-2526, 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38507746
20.
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Br J Haematol
; 161(4): 508-16, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23480528